ABSTRACT To evaluate hemodynamic, angiographic, and biological effects of a single bolus of urokinase, an open descriptive trial was conducted in a homogeneous group of 14 patients with acute life-threatening pulmonary emboli and without prior cardiopulmonary disease. For every patient the efficacy of the treatment was evaluated by comparing control and posttherapeutic values after the bolus injection of 15,000 IU/kg body weight urokinase (urinary source) administered in 10 min in the right atrium, followed by continuous intravenous full-dose heparin therapy. In two patients clinical status, hemodynamics, vascular obstruction, and biological (fibrinogen and plasminogen levels) parameters remained unchanged. One of these two patients died, making the mortality rate for the whole group 7%. Twelve of 14 patients showed rapid clinical improvement. Evaluation at 12 hr demonstrated significant decreases in pulmonary vascular obstruction (Miller index, 34%), total pulmonary vascular resistances (37%), and fibrinogen and plasminogen levels (41% and 40%, respectively), without any significant change in cardiac index. The hemodynamic sequential measurements performed (1, 3, 6, and 12 hr) in seven of the 12 improved patients showed that the greatest percentage of the total hemodynamic improvement occurred within the first 3 hr after bolus administration of urokinase. No severe hemorrhagic complications were observed. Because of its rapid efficacy and its low cost, the bolus technique appeared particularly useful in the treatment of patients with acute life-threatening pulmonary emboli.
SEVERE, life-threatening pulmonary emboli associated with clinical shock, right ventricular failure, seizures, or syncope require early, rapid, and effective therapy.
Under these emergency conditions, thrombolytic agents as well as pulmonary embolectomy must be the first line of therapy to obtain a prompt reduction of the right ventricular afterload. Previously reported data concerning early changes in hemodynamics are not available in studies that used the continuous intravenous infusion of either high doses of urokinase (4000 IU/kg/hr for 12 to 24 hr) or high doses of streptokinase (100,000 lU/hr for 24 The degree of the pulmonary arterial occlusion was assessed by the severity score system proposed by Miller et al.6 This system provides a score from 0 to 34, with a maximum of 16 for the thrombus itself and 18 for the peripheral perfusion state.
Hemodynamics and blood gas analysis. In all 14 patients, right heart catheterization was performed with a thermodilution balloon-tipped catheter (Edwards Laboratories) introduced percutaneously via an antecubital vein and floated to a position from which satisfactory readings could be obtained for pulmonary arterial pressure. Pulmonary wedge pressure could be obtained in only six patients. Intravascular pressures were measured relative to atmosphere by reference to a zero level located at midthoracic height (Statham P23dB transducers) and were recorded on photographic paper. (VR6; Electronics for Medicine). Instantaneous pressures were measured over three consecutive respiratory cycles and integrated electronically. All hemodynamic measurements were carried out with patients breathing room air and off previous supportive drugs and oxygen therapy for at least 10 min. Arterial and venous blood samples were analyzed for pH and blood gases (partial pressures of oxygen and carbon dioxide, Pao2 and Paco2) by Radiometers electrodes. Cardiac index (liters/min/m2 body surface area) was measured by the thermodilution method (mean of three measurements) in eight patients and calculated in the six others from aVO2 differences and tabulated values of oxygen consumption.
Total pulmonary vascular resistance (mm Hg/liter/min/m2) was calculated as mean pulmonary arterial pressure over cardiac index. Venous blood was drawn for routine measurements, coagulation tests (calcium recalcification time and thrombin time), and fibrinogen7 and plasminogen8 measurements.
Treatment regimen. Urokinase was injected within a mean of 4 hr after hospital admittance. For all patients, 15,000 IU/kg body weight urokinase (urinary source) was injected as single bolus within 10 min in the proximal orifice of the thermodilution balloon-tipped catheter located in the right atrium. There were no subsequent injections of urokinase. The intravenous heparin treatment was started immediately after the completion of the bolus injection of urokinase by means of the same constant electric infusion pump. The initial daily dose of Na-heparin was fixed at 500 IU/kg body weight; this dose was subsequently adjusted at the third hour and every 12 hr to obtain a thrombin time value over 2 min and a calcium recalcification time of 2 to 2.5 times the control values.
Assessment of efficacy of treatment. Because of the emergency situation, complete clinical information could not be collected for every patient. The assessment of the efficacy of treat-CIRCULATION 
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---. In the second patient hemodynamic measurements did not show any improvement in mean pulmonary arterial pressure or total pulmonary vascular resistance; the patient showed clinical deterioration, leading to an emergency embolectomy under total cardiopulmonary bypass associated with an inferior vena caval interruption. During this procedure, massive, recent thrombi were found in the pulmonary arterial trunk. Unfortunately, in spite of postsurgical heparinization, this patient died on postoperative day 8 from recurrent emboli. It is noteworthy that in these two patients, the pretreatment and posttreatment fibrinogen and plasminogen levels did not show any significant variation.
Complications and side effects during the first 24 hr. No severe blood loss requiring transfusion was observed; 864 likewise, there was no significant fall in hemoglobin concentration (before and after urokinase, 13.7 ± 1. 8 vs 14.2 ± 1.8 g/100 ml). Only minor bleeding occurred at the catheterization sites, which can be explained by the preferential use of basilic veins for all invasive investigations.
Discussion
The severity of the conditions of patients included in this study, assessed clinically, angiographically, and hemodynamically, was similar to that described by others in reports on life-threatening pulmonary emboli.6 9 The efficacy of the 15,000 IU/kg single bolus injection of urokinase estimated in a homogeneous group of critically ill patients was demonstrated in 85% (12/14 patients) by a mean hemodynamic and angiographic improvement of about 30% at 12 hr. These results are similar to those previously reported by Dickie et al. 4 In addition it is worthwhile to note that the values measured at 12 hr were of the same magnitude as those obtained by the continuous infusion of urokinase (Urokinase Pulmonary Embolism Trial).' 2 The hemodynamic improvement brought about by the bolus technique could be considered moderate; however, the relationship between total pulmonary vascular resistance and the level of pulmonary vascular obstruction was not linear (figure 2) but showed a hyperbolic tendency, with a dramatic increase in resistances when vascular obstruction exceeded about 60%. Thus even a slight decrease in pulmonary obstruction can induce a significant lowering of the right ventricular strain, placing these patients' values on a less steep part of the total pulmonary vascular resistance/pulmonary vascular obstruction curve. In the 12 improved patients, a moderate but significant drop in both fibrinogen (10 patients) and plasminogen levels (eight patients) was observed at 12 hr. This contrasts sharply with the two unsuccessfully treated patients, in whom these biological parameters remain unchanged. The reasons for the lack of therapeutic activity of urokinase in these two patients are unclear.
A major interest of this study concerns the hemodynamic sequential monitoring made in the acute phase during the first 12 hr after bolus injection of urokinase ( figure 1) ; the greatest part of the total hemodynamic improvement occurred within the first 3 tomy. Early measurements of pulmonary hemodynamics during the acute phase have also been previously reported in two studies.4 10 Dickie et al. 4 showed in four patients without prior cardiopulmonary disease a 32% decrease of mean pulmonary arterial pressure at the fourth hour after bolus injection of urokinase; in the Urokinase Pulmonary Embolism Trial study and for the only eight sequentially monitored patients, a decrease of mean pulmonary arterial pressure was shown at 4 hr (24%) and at 6 hr (32%) after the completion of the injection of an initial loading dose of 4000 IU/kg body weight and the perfusion of a maintenance dose of 4000 IU/kg/hr. It is noteworthy that the kinetics of hemodynamic improvement obtained at 4 hr with the continuous infusion of a total amount of 20,000 IU/kg was close to that obtained with the single injection of a bolus of 15,000 IU/kg.
The rapid decline in pulmonary hypertension after the bolus injection of urokinase could suggest a vasodilatory effect of the drug; this seems unlikely, however, since the decrease in pulmonary pressures and resistances was associated with the improvement in angiographic vascular obstruction. In addition there was no angiographic change in the two hemodynamically unimproved patients.
On purely clinical grounds, it is noteworthy that this 
